Sucampo Pharmaceuticals, a global biopharmaceutical company, announced that Sucampo and R-Tech Ueno, Ltd. (RTU), have entered into a stipulation and licence agreement with Par Pharmaceutical, Inc. (Par). The agreement states that in limited circumstances, Sucampo or RTU would grant Par a licence for a generic version of the RESCULA (unoprostone isopropyl ophthalmic solution) 0.15 per cent product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Par had previously submitted an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market, sell, and use a generic version of RESCULA.